Quick Answer
Nautilus Biotechnology, Inc. reported R&D Expense of $41.11 million for fiscal year 2025.
Nautilus Biotechnology, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $41.11M | -18.6% |
| 2024 | $50.48M | +6.8% |
| 2023 | $47.25M | +25.4% |
| 2022 | $37.67M | +28.3% |
| 2021 | $29.35M | +136.1% |
| 2020 | $12.43M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $9.61M | -21.8% | -7.6% |
| June 30, 2025 | $10.39M | -16.4% | -9.9% |
| March 31, 2025 | $11.54M | -10.8% | -6.1% |
| September 30, 2024 | $12.29M | +2.4% | -1.2% |
| June 30, 2024 | $12.44M | +4.4% | -3.8% |
| March 31, 2024 | $12.93M | +18.9% | +7.8% |
| September 30, 2023 | $12.00M | +25.3% | +0.7% |
| June 30, 2023 | $11.91M | +34.5% | +9.5% |
- Nautilus Biotechnology, Inc. showed a decrease of -18.6% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Nautilus Biotechnology, Inc.’s r&d expense has grown by 230.7% (from $12.43 million to $41.11 million).
- The most recent figure is from Nautilus Biotechnology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: